BACKGROUND: There are limited data regarding the impact of body mass index (BMI) on outcomes in advanced breast cancer, especially in patients treated with endocrine therapy (ET) + cyclin-dependent kinase 4/6 inhibitors. METHODS: A pooled analysis of individual patient-level data from MONARCH 2 and 3 trials was performed. Patients were classified according to baseline BMI into underweight (<18.5 kg/m2), normal (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2), and obese (≥30 kg/m2) and divided into 2 treatment groups: abemaciclib + ET vs placebo + ET. The primary endpoint was progression-free survival (PFS) according to BMI in each treatment group. Secondary endpoints were response rate, adverse events according to BMI, and loss of weight (≥5% from baseline) during treatment. RESULTS: This analysis included 1138 patients (757 receivedabemaciclib + ET and 381 placebo + ET). There was no difference in PFS between BMI categories in either group, although normal-weight patients presented a numerically higher benefit with abemaciclib + ET (Pinteraction = .07). Normal and/or underweight patients presented higher overall response rate in the abemaciclib + ET group compared with overweight and/or obese patients (49.4% vs 41.6%, odds ratio = 0.73, 95% confidence interval = 0.54 to 0.99) as well as higher neutropenia frequency (51.0% vs 40.4%, P = .004). Weight loss was more frequent in the abemaciclib + ET group (odds ratio = 3.23, 95% confidence interval = 2.09 to 5.01). CONCLUSIONS: Adding abemaciclib to ET prolongs PFS regardless of BMI, showing that overweight or obese patients also benefit from this regimen. Our results elicit the possibility of a better effect of abemaciclib in normal and/or underweight patients compared with overweight and/or obese patients. More studies analyzing body composition parameters in patients under treatment with cyclin-dependent kinase 4/6 inhibitors may further clarify this hypothesis.
RCT Entities:
BACKGROUND: There are limited data regarding the impact of body mass index (BMI) on outcomes in advanced breast cancer, especially in patients treated with endocrine therapy (ET) + cyclin-dependent kinase 4/6 inhibitors. METHODS: A pooled analysis of individual patient-level data from MONARCH 2 and 3 trials was performed. Patients were classified according to baseline BMI into underweight (<18.5 kg/m2), normal (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2), and obese (≥30 kg/m2) and divided into 2 treatment groups: abemaciclib + ET vs placebo + ET. The primary endpoint was progression-free survival (PFS) according to BMI in each treatment group. Secondary endpoints were response rate, adverse events according to BMI, and loss of weight (≥5% from baseline) during treatment. RESULTS: This analysis included 1138 patients (757 received abemaciclib + ET and 381 placebo + ET). There was no difference in PFS between BMI categories in either group, although normal-weight patients presented a numerically higher benefit with abemaciclib + ET (Pinteraction = .07). Normal and/or underweight patients presented higher overall response rate in the abemaciclib + ET group compared with overweight and/or obesepatients (49.4% vs 41.6%, odds ratio = 0.73, 95% confidence interval = 0.54 to 0.99) as well as higher neutropenia frequency (51.0% vs 40.4%, P = .004). Weight loss was more frequent in the abemaciclib + ET group (odds ratio = 3.23, 95% confidence interval = 2.09 to 5.01). CONCLUSIONS: Adding abemaciclib to ET prolongs PFS regardless of BMI, showing that overweight or obesepatients also benefit from this regimen. Our results elicit the possibility of a better effect of abemaciclib in normal and/or underweight patients compared with overweight and/or obesepatients. More studies analyzing body composition parameters in patients under treatment with cyclin-dependent kinase 4/6 inhibitors may further clarify this hypothesis.
Authors: Marian L Neuhouser; Aaron K Aragaki; Ross L Prentice; JoAnn E Manson; Rowan Chlebowski; Cara L Carty; Heather M Ochs-Balcom; Cynthia A Thomson; Bette J Caan; Lesley F Tinker; Rachel Peragallo Urrutia; Jennifer Knudtson; Garnet L Anderson Journal: JAMA Oncol Date: 2015-08 Impact factor: 31.777
Authors: Bette J Caan; Jeffrey A Meyerhardt; Candyce H Kroenke; Stacey Alexeeff; Jingjie Xiao; Erin Weltzien; Elizabeth Cespedes Feliciano; Adrienne L Castillo; Charles P Quesenberry; Marilyn L Kwan; Carla M Prado Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-05-15 Impact factor: 4.254
Authors: Xiaoli Hou; Yongzhao Zhang; Wei Li; Alexander J Hu; Chi Luo; Wenhui Zhou; Jamie K Hu; Stefano G Daniele; Jinfeng Wang; Jinghao Sheng; Yongsheng Fan; Andrew S Greenberg; Stephen R Farmer; Miaofen G Hu Journal: Nat Commun Date: 2018-03-09 Impact factor: 14.919
Authors: Camille Lehuédé; Xia Li; Stéphanie Dauvillier; Charlotte Vaysse; Camille Franchet; Emily Clement; David Esteve; Mélanie Longué; Léonor Chaltiel; Sophie Le Gonidec; Ikrame Lazar; Aline Geneste; Charles Dumontet; Philippe Valet; Laurence Nieto; Frédérique Fallone; Catherine Muller Journal: Breast Cancer Res Date: 2019-01-17 Impact factor: 6.466
Authors: Christian Ohmann; Rita Banzi; Steve Canham; Serena Battaglia; Mihaela Matei; Christopher Ariyo; Lauren Becnel; Barbara Bierer; Sarion Bowers; Luca Clivio; Monica Dias; Christiane Druml; Hélène Faure; Martin Fenner; Jose Galvez; Davina Ghersi; Christian Gluud; Trish Groves; Paul Houston; Ghassan Karam; Dipak Kalra; Rachel L Knowles; Karmela Krleža-Jerić; Christine Kubiak; Wolfgang Kuchinke; Rebecca Kush; Ari Lukkarinen; Pedro Silverio Marques; Andrew Newbigging; Jennifer O'Callaghan; Philippe Ravaud; Irene Schlünder; Daniel Shanahan; Helmut Sitter; Dylan Spalding; Catrin Tudur-Smith; Peter van Reusel; Evert-Ben van Veen; Gerben Rienk Visser; Julia Wilson; Jacques Demotes-Mainard Journal: BMJ Open Date: 2017-12-14 Impact factor: 2.692
Authors: Maria Alice Franzoi; Matteo Lambertini; Marcello Ceppi; Marco Bruzzone; Evandro de Azambuja Journal: Breast Cancer Res Treat Date: 2022-01-25 Impact factor: 4.872
Authors: Natansh D Modi; Jin Quan Eugene Tan; Andrew Rowland; Bogda Koczwara; Ahmad Y Abuhelwa; Ganessan Kichenadasse; Ross A McKinnon; Michael D Wiese; Michael J Sorich; Ashley M Hopkins Journal: NPJ Breast Cancer Date: 2021-03-22
Authors: Danielle B Tometich; Kelly A Hyland; Hatem Soliman; Heather S L Jim; Laura Oswald Journal: Cancers (Basel) Date: 2020-12-08 Impact factor: 6.639